Crossmark

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis

Crossref DOI link: https://doi.org/10.1016/j.medcli.2021.06.014

Published Print: 2022-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Fernández-Ruiz, Mario http://orcid.org/0000-0002-0315-8001
López-Medrano, Francisco http://orcid.org/0000-0001-5333-7529
Carretero, Octavio http://orcid.org/0000-0003-1839-3853
Parra, Patricia http://orcid.org/0000-0003-3446-1991
Ruiz-Merlo, Tamara http://orcid.org/0000-0003-4748-8288
Aguado, José María http://orcid.org/0000-0002-9520-8255
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III (COV20/00181, CP18/00073)

Ministerio de Ciencia e Innovación (COV20/00181, CP18/00073)

European Regional Development Fund (COV20/00181, CP18/00073)
License Information

Text and Data Mining valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01

stm-asf valid from 2022-06-01
More Information

This article is maintained by: Elsevier

Article Title: Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2021.06.014

Content Type: simple-article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.